

DNA39427-1179	ATCC 209395	October 17, 1997
DNA40603-1232	ATCC 209486	November 21, 1997
DNA43466-1225	ATCC 209490	November 21, 1997
DNA43046-1225	ATCC 209484	November 21, 1997
DNA35668-1171	ATCC 209371	October 16, 1997
DNA77624-2515	ATCC 203553	December 22, 1998--

In the Claims:

Please cancel claims 48, 53 and 54, without prejudice.

Please amend claims 39-44 and 52 as follows:

39. (Once amended) An isolated nucleic acid having at least 80% nucleic acid sequence identity to:

(a) a nucleic acid sequence encoding the polypeptide shown in Figure 102 (SEQ ID NO: 290);

(b) a nucleic acid sequence encoding the polypeptide shown in Figure 102 (SEQ ID NO: 290), lacking its associated signal peptide;

(c) a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 102 (SEQ ID NO: 290);

(d) the nucleic acid sequence shown in Figure 101 (SEQ ID NO: 289);

(e) the full-length coding sequence of the nucleic acid sequence shown in Figure 101 (SEQ ID NO: 289); or

(f) the full-length coding sequence of the cDNA deposited under ATCC accession number 209927,

wherein said polypeptide induces proliferation of stimulated lymphocytes in a mixed lymphocyte reaction.

40. (Once amended) The isolated nucleic acid of Claim 39 having at least 85% nucleic acid sequence identity to:

(a) a nucleic acid sequence encoding the polypeptide shown in Figure 102 (SEQ ID NO: 290);

(b) a nucleic acid sequence encoding the polypeptide shown in Figure 102 (SEQ ID NO: 290), lacking its associated signal peptide;

(c) a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 102 (SEQ ID NO: 290);

(d) the nucleic acid sequence shown in Figure 101 (SEQ ID NO: 289);

(e) the full-length coding sequence of the nucleic acid sequence shown in Figure 101 (SEQ ID NO: 289); or

(f) the full-length coding sequence of the cDNA deposited under ATCC accession number 209927,

wherein said polypeptide induces proliferation of stimulated lymphocytes in a mixed lymphocyte reaction.

41. (Once amended) The isolated nucleic acid of Claim 39 having at least 90% nucleic acid sequence identity to:

(a) a nucleic acid sequence encoding the polypeptide shown in Figure 102 (SEQ ID NO: 290);

(b) a nucleic acid sequence encoding the polypeptide shown in Figure 102 (SEQ ID NO: 290), lacking its associated signal peptide;

(c) a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 102 (SEQ ID NO: 290);

(d) the nucleic acid sequence shown in Figure 101 (SEQ ID NO: 289);

(e) the full-length coding sequence of the nucleic acid sequence shown in Figure 101 (SEQ ID NO: 289); or

(f) the full-length coding sequence of the cDNA deposited under ATCC accession number 209927,

wherein said polypeptide induces proliferation of stimulated lymphocytes in a mixed lymphocyte reaction.

42. (Once amended) The isolated nucleic acid of Claim 39 having at least 95% nucleic acid sequence identity to:

(a) a nucleic acid sequence encoding the polypeptide shown in Figure 102 (SEQ ID NO: 290);

(b) a nucleic acid sequence encoding the polypeptide shown in Figure 102 (SEQ ID NO: 290), lacking its associated signal peptide;

(c) a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 102 (SEQ ID NO: 290);

(d) the nucleic acid sequence shown in Figure 101 (SEQ ID NO: 289);

(e) the full-length coding sequence of the nucleic acid sequence shown in Figure 101 (SEQ ID NO: 289); or

(f) the full-length coding sequence of the cDNA deposited under ATCC accession number 209927,

wherein said polypeptide induces proliferation of stimulated lymphocytes in a mixed lymphocyte reaction.

43. (Once amended) The isolated nucleic acid of Claim 39 having at least 99% nucleic acid sequence identity to:

(a) a nucleic acid sequence encoding the polypeptide shown in Figure 102 (SEQ ID NO: 290);

(b) a nucleic acid sequence encoding the polypeptide shown in Figure 102 (SEQ ID NO: 290), lacking its associated signal peptide;

(c) a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 102 SEQ ID NO: 290);

(d) the nucleic acid sequence shown in Figure 101 (SEQ ID NO: 289);

(e) the full-length coding sequence of the nucleic acid sequence shown in Figure 101 (SEQ ID NO: 289); or

(f) the full-length coding sequence of the cDNA deposited under ATCC accession number 209927,

wherein said polypeptide induces proliferation of stimulated lymphocytes in a mixed lymphocyte reaction.

44. (Once amended) An isolated nucleic acid comprising:

(a) a nucleic acid sequence encoding the polypeptide shown in Figure 102 (SEQ ID NO: 290);

(b) a nucleic acid sequence encoding the polypeptide shown in Figure 102 (SEQ ID NO: 290), lacking its associated signal peptide;

(c) a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 102 SEQ ID NO: 290);

(d) the nucleic acid sequence shown in Figure 101 (SEQ ID NO: 289);

(e) the full-length coding sequence of the nucleic acid sequence shown in Figure 101 (SEQ ID NO: 289); or

(f) the full-length coding sequence of the cDNA deposited under ATCC accession number 209927,

wherein said polypeptide induces proliferation of stimulated lymphocytes in a mixed lymphocyte reaction.

52. (Once amended) An isolated nucleic acid that hybridizes to, under stringent conditions,:

(a) a nucleic acid sequence encoding the polypeptide shown in Figure 102 (SEQ ID NO: 290);

(b) a nucleic acid sequence encoding the polypeptide shown in Figure 102 (SEQ ID NO 290), lacking its associated signal peptide;

(c) a nucleic acid sequence encoding the extracellular domain of the polypeptide shown in Figure 102 SEQ ID NO: 290);

(d) the nucleic acid sequence shown in Figure 101 (SEQ ID NO: 289);

(e) the full-length coding sequence of the nucleic acid sequence shown in Figure 101 (SEQ ID NO: 289); or

(f) the full-length coding sequence of the cDNA deposited under ATCC accession number 209927,

wherein said polypeptide induces proliferation of stimulated lymphocytes in a mixed lymphocyte reaction, and

wherein said stringent conditions are hybridization in 50% formamide, 5 x SSC (0.75 M NaCl, 0.075 M sodium citrate), 50 mM sodium phosphate (pH 6.8), 0.1% sodium pyrophosphate, 5 x Denhardt's solution, sonicated salmon sperm DNA (50 µg/ml), 0.1% SDS, and 10% dextran sulfate at 42°C, with washes at 42°C in 0.2 x SSC (sodium chloride/sodium citrate) and 50% formamide at 55°C, followed by a high-stringency wash consisting of 0.1 x SSC containing EDTA at 55°C.

#### REMARKS

The foregoing amendments in the specification and claims are of formal nature and do not introduce new matter.